Innoviva Inventory Turnover Ratio 2010-2023 | INVA

Innoviva inventory turnover ratio from 2010 to 2023. Inventory turnover ratio can be defined as a ratio showing how many times a company's inventory is sold and replaced over a period.
Innoviva Inventory Turnover Ratio Historical Data
Date
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.925B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $714.182B 118.93
Novo Nordisk (NVO) Denmark $558.743B 46.03
Johnson & Johnson (JNJ) United States $355.491B 14.14
Merck (MRK) United States $318.503B 83.83
AbbVie (ABBV) United States $287.341B 14.61
AstraZeneca (AZN) United Kingdom $213.711B 18.94
Novartis AG (NVS) Switzerland $198.225B 13.73
Pfizer (PFE) United States $146.433B 14.13
Sanofi (SNY) $116.185B 10.46